• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Co-Development of Drugs and Pharmacogenomics-Based Diagnostics in Oncology

        互联网

        431
        The molecular diagnostic industry continues to grow at a double-digit pace to meet increasing demand for the integration of diagnostic procedures with the selection of therapy, and the development of personalized drugs whose administration is guided by test results. Newly developed anticancer drugs are targeted to tumor-specific gene and protein signatures that may ultimately require co-approval of diagnostic and therapeutic products by the regulatory agencies. At the same time, an increasingly educated public using the Internet and other resources are demanding more and more information about their specific forms of cancer and how they might be arrested or cured with new therapies custom-designed for their individual clinical status. To respond to this demand, major pharmaceutical companies will either partner with diagnostics companies or develop their own in-house capabilities allowing them to efficiently produce more effective and less toxic integrated personalized medicine “drug and test ” products. For diagnostic laboratories, surgical pathologists, functional imagers, and oncologists, this integration of diagnostics and therapeutics represents a major new opportunity to further advance cancer care as a paradigm of the new medicine based on the use of test results for drug selection, dosage, route of administration, and multidrug combinations.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序